Overview

Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study

Status:
Completed
Trial end date:
2017-04-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the treatment success of fexinidazole, at one year follow-up visit, in HAT stage 1 and early stage 2 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Drugs for Neglected Diseases